281 related articles for article (PubMed ID: 16888370)
1. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
2. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P
Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
[TBL] [Abstract][Full Text] [Related]
3. Parathyroidectomy leads to decreased blood lead levels in patients with refractory secondary hyperparathyroidism.
Chu P; Wu CC; Chen CC; Lu KC
Bone; 2012 May; 50(5):1032-8. PubMed ID: 22373954
[TBL] [Abstract][Full Text] [Related]
4. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
5. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
Lu KC; Ma WY; Yu JC; Wu CC; Chu P
Clin Endocrinol (Oxf); 2012 May; 76(5):634-42. PubMed ID: 22007930
[TBL] [Abstract][Full Text] [Related]
6. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
7. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
8. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
9. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
Wu CC; Chang JH; Chen CC; Su SB; Yang LK; Ma WY; Zheng CM; Diang LK; Lu KC
Tohoku J Exp Med; 2011 Mar; 223(3):153-9. PubMed ID: 21350317
[TBL] [Abstract][Full Text] [Related]
10. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
11. [Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays].
Ureña P; Prieur P; Pétrover M
Presse Med; 1996 Oct; 25(29):1320-5. PubMed ID: 8942941
[TBL] [Abstract][Full Text] [Related]
12. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
14. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
15. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
[TBL] [Abstract][Full Text] [Related]
16. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels.
Borazan A; Ustün H; Cefle A; Sekitmez N; Yilmaz A
J Int Med Res; 2003; 31(6):489-96. PubMed ID: 14708413
[TBL] [Abstract][Full Text] [Related]
18. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
[TBL] [Abstract][Full Text] [Related]
19. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls.
Cheng S; Tylavsky F; Kröger H; Kärkkäinen M; Lyytikäinen A; Koistinen A; Mahonen A; Alen M; Halleen J; Väänänen K; Lamberg-Allardt C
Am J Clin Nutr; 2003 Sep; 78(3):485-92. PubMed ID: 12936933
[TBL] [Abstract][Full Text] [Related]
20. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
